

CUMULUS NEUROSCIENCE LIMITED

**Company Registration Number:
NI628481 (Northern Ireland)**

Unaudited abridged accounts for the year ended 31 December 2020

Period of accounts

Start date: 01 January 2020

End date: 31 December 2020

CUMULUS NEUROSCIENCE LIMITED

Contents of the Financial Statements for the Period Ended 31 December 2020

Balance sheet

Notes

CUMULUS NEUROSCIENCE LIMITED

Balance sheet

As at 31 December 2020

| | <i>Notes</i> | 2020 | 2019 |
|--|--------------|------------------|----------------|
| | | £ | £ |
| Fixed assets | | | |
| Tangible assets: | 3 | 19,702 | 23,871 |
| Total fixed assets: | | <u>19,702</u> | <u>23,871</u> |
| Current assets | | | |
| Debtors: | | 528,942 | 200,112 |
| Cash at bank and in hand: | | 6,764,060 | 264,200 |
| Total current assets: | | <u>7,293,002</u> | <u>464,312</u> |
| Creditors: amounts falling due within one year: | | (590,895) | (140,862) |
| Net current assets (liabilities): | | <u>6,702,107</u> | <u>323,450</u> |
| Total assets less current liabilities: | | 6,721,809 | 347,321 |
| Creditors: amounts falling due after more than one year: | | (6,127,895) | (109,303) |
| Total net assets (liabilities): | | <u>593,914</u> | <u>238,018</u> |
| Capital and reserves | | | |
| Called up share capital: | | 85 | 69 |
| Share premium account: | | 376,402 | 1,008,001 |
| Other reserves: | | 7 | 7 |
| Profit and loss account: | | 217,420 | (770,059) |
| Shareholders funds: | | <u>593,914</u> | <u>238,018</u> |

The notes form part of these financial statements

CUMULUS NEUROSCIENCE LIMITED

Balance sheet statements

For the year ending 31 December 2020 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company's profit & loss account.

**This report was approved by the board of directors on 27 January 2021
and signed on behalf of the board by:**

Name: Ronan Cunningham
Status: Director

The notes form part of these financial statements

CUMULUS NEUROSCIENCE LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2020

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

CUMULUS NEUROSCIENCE LIMITED

Notes to the Financial Statements for the Period Ended 31 December 2020

2. Employees

| | <i>2020</i> | <i>2019</i> |
|---|-------------|-------------|
| Average number of employees during the period | 21 | 21 |

CUMULUS NEUROSCIENCE LIMITED

Notes to the Financial Statements for the Period Ended 31 December 2020

3. Tangible Assets

| | Total |
|-----------------------|----------------|
| Cost | £ |
| At 01 January 2020 | 87,252 |
| Additions | 18,105 |
| At 31 December 2020 | <u>105,357</u> |
| Depreciation | |
| At 01 January 2020 | 63,381 |
| Charge for year | 22,274 |
| At 31 December 2020 | <u>85,655</u> |
| Net book value | |
| At 31 December 2020 | <u>19,702</u> |
| At 31 December 2019 | <u>23,871</u> |

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.